(Q33642535)

28 July 2017

1 reference

title

Vaccines and antibodies in the prevention and treatment of sepsis (English)

1 reference

28 July 2017

0 references

Bhattacharjee AK

1

1 reference

28 July 2017

Cross AS

series ordinal

2

1 reference

28 July 2017

publication date

1 June 1999

1 reference

Infectious Disease Clinics of North America

28 July 2017

published in

1 reference

28 July 2017

volume

13

1 reference

28 July 2017

issue

2

1 reference

28 July 2017

page(s)

355-69, vii

1 reference

Monoclonal antibody to endotoxin attenuates hemorrhage-induced lung injury and mortality in rats.

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Antibodies to Lipopolysaccharides after Immunization of Humans with the Rough Mutant Escherichia coli J5

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Relationship of preoperative antiendotoxin core antibodies and adverse outcomes following cardiac surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Affinity-purified Escherichia coli J5 lipopolysaccharide-specific IgG protects neutropenic rats against gram-negative bacterial sepsis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Treatment of Gram-Negative Septic Shock with Human IgG Antibody to Escherichia coli J5: A Prospective, Double-Blind, Randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Immunogenicity of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered to victims of acute trauma

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Antibody titres to a rough-mutant strain of Escherichia coli in patients undergoing allogeneic bone-marrow transplantation. Evidence of a protective effect against graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Human vaccination with Escherichia coli J5 mutant induces cross-reactive bactericidal antibody against Neisseria gonorrhoeae lipooligosaccharide

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Monoclonal antibodies that distinguish inner core, outer core, and lipid A regions of Pseudomonas aeruginosa lipopolysaccharide.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Immunization with rough mutants of Salmonella minnesota: initial studies in human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Immunoprophylaxis against klebsiella and pseudomonas aeruginosa infections. The Federal Hyperimmune Immunoglobulin Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Preliminary Study on Treatment of Septic Shock Patients with Antilipopolysaccharide IgG from Blood Donors

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Monoclonal anti-lipid A IgM antibodies HA-1A and E-5 recognize distinct epitopes on lipopolysaccharide and lipid A

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Septicemia in 980 patients at a university hospital in Berlin: prospective studies during 4 selected years between 1979 and 1989

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Bloodstream infections at a Norwegian university hospital, 1974-1979 and 1988-1989: changing etiology, clinical features, and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Cross-protection by anti-core glycolipid antibodies: evidence from animal experiments

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Evaluation of protection by two endotoxin-neutralizing IgM monoclonal antibodies in different peritonitis models.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: a prospective double-blind study. J5 study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Serological characterisation of anti-endotoxin sera directed against the conjugates of oligosaccharide core of Escherichia coli type R1, R2, R3, J5 and Salmonella Ra with tetanus toxoid.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Anti-endotoxin antibodies directed against Escherichia coli R-1 oligosaccharide core-tetanus toxoid conjugate bind to smooth, live bacteria and smooth lipopolysaccharides and attenuate their tumor necrosis factor stimulating activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Structural elucidation of the lipopolysaccharide core region of the O-chain-deficient mutant strain A28 from Pseudomonas aeruginosa serotype 06 (International Antigenic Typing Scheme)

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Characterization of murine monoclonal antibodies to Escherichia coli J5

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Chemical structure of the core region of Escherichia coli J-5 lipopolysaccharide

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Sequential anti-core glycolipid immunoglobulin antibody activities in patients with and without septic shock and their relation to outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Biosynthesis and structure of the core region of the lipopolysaccharide in Salmonella typhimurium

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Specificity and cross-reactivity of monoclonal antibodies reactive with the core and lipid A regions of bacterial lipopolysaccharide.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

The enzymatic synthesis of lipid A: molecular structure and biologic function of monosaccharide precursors.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Characterization of the human antibody response to an Escherichia coli O111:B4 (J5) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Identification of a novel heptoglycan of alpha1-->2-linked D-glycero-D-manno-heptopyranose. Chemical and antigenic structure of lipopolysaccharides from Klebsiella pneumoniae ssp. pneumoniae rough strain R20 (O1-:K20-)

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

A murine monoclonal antibody defines a unique epitope shared by Klebsiella lipopolysaccharides

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Release of tumor necrosis factor: an innate host characteristic that may contribute to the outcome of meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Variable cross-reactivity of Pseudomonas aeruginosa lipopolysaccharide-code-specific monoclonal antibodies and its possible relationship with serotype

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970079-9

7 January 2021

10.1016/S0891-5520(05)70079-9

Identifiers

DOI

1 reference

28 July 2017

1 reference